Results 231 to 240 of about 882,596 (264)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Research priorities in the field of interprofessional healthcare education: a James Lind Alliance Priority Setting Partnership. [PDF]

open access: yesBMJ Open
Kumlien C   +7 more
europepmc   +1 more source

Preserving music reward in age-related hearing loss through training and adaptation. [PDF]

open access: yesBMC Geriatr
Gao E   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy